Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Ind-Swift Director N R...

    Ind-Swift Director N R Munjal arrested for alleged Tax Evasion of Rs 5 crore

    Farhat NasimWritten by Farhat Nasim Published On 2018-12-11T09:30:10+05:30  |  Updated On 11 Dec 2018 9:30 AM IST
    Ind-Swift Director N R Munjal arrested for alleged Tax Evasion of Rs 5 crore

    New Delhi: In a major setback to a pharma firm, the director of Ind-Swift pharma was recently arrested by the police on charges of Tax Evasion, Forgery and cheating


    Through a recent BSE filing Ind-Swift a pharmaceutical manufacturing and marketing company confirmed that Mr N R Munjal, Director of the Company has been detained by the Investigating Authorities for seeking more details about the matter.


    The disclosure was under regulation 30 of Listing Obligations and Disclosure Requirements Regulations, 2015.


    Signed by the company secretary Amrender Kumar Yadav the disclosure read "Pursuant to Regulation 30 of SEBl (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our earlier disclosure dated 3rd December 2018, this is to inform that Mr N R Munjal, Director of the Company has been detained by the Investigating Authorities for seeking more details about the matter."


    Indian Express reports that the director of Ind-Swift Laboratories Ltd, N R Munjal, was arrested by Chandigarh Police on December 3 in connection with a forgery and cheating case, along with the non-payment of tax dues. He was sent to judicial custody in an alleged tax evasion case tuning to Rs 5.09 crore.


    The accused was produced in the court after a couple of days remand by the police. The prosecution did not seek any further remand and thus he was sent to judicial custody.


    Munjal's counsel moved an application to the court for bail, acting on which the court has instructed the police to act accordingly since Munjal suffers from a hernia and diabetes.


    Ind-Swift Ltd. is an existing profit making, dividend paying company engaged in the formulation of injectables and ophthalmic products at Panchkula, Haryana. It was incorporated as a limited company on 06.06.1986 and was granted the certificate of commencement of business on 15.12.1986. In July'89 the Company got its project for manufacture of injectables and trading of pharmaceutical products appraised from Haryana Financial Corporation (HFC) which was implemented in December'90 for a total cost of 49.77 lakhs.


    Also Read: CGHS medicine supplier SURRENDERS Rs 200 crore black money

    bse filingChandigarhcheatingdetainedDirectordisclosureforgeryHaryanaind swiftinvestigating authoritiesjudicial custodyn r munjalregulation 30SEBItax duetax evasion
    Source : With inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok